Future Medicine Submits Preliminary Review Application for Listing... KOSDAQ Transfer Listing

Future Medicine, a global new drug development company based on nucleosides, announced on the 23rd that it submitted a preliminary listing examination application to the Korea Exchange on the 20th for its transfer listing on KOSDAQ. The lead underwriter is NH Investment & Securities.

Founded in 2015, Future Medicine is a new drug development company that owns the nucleoside-based new drug candidate discovery platform ‘FOCUS (Futuremedicine Origin Compound Library Universal System)’ developed in-house. Future Medicine is developing global new drugs in the nucleoside series based on the technological superiority of CEO Jeong Nak-sin, who has continued nucleoside research for over 40 years.

Future Medicine has secured multiple pipelines including treatments for metabolic diseases, anticancer drugs, and antiviral drugs, based on its competitiveness as the world’s first to successfully synthesize 3rd and 4th generation nucleosides that overcome the toxicity and other drawbacks of previous generations.

The representative pipeline is ‘FM101,’ which is being developed as a treatment for Non-Alcoholic SteatoHepatitis (NASH). Unlike existing drugs under development, it is a NASH drug candidate targeting the ‘A3 adenosine receptor.’ It has excellent selectivity and safety for the target, and compared to other drugs under development, it has superior anti-inflammatory and anti-fibrotic effects. Currently, global Phase 2 clinical trials including in Europe are underway, and in 2020, Future Medicine achieved a technology transfer of domestic and Chinese rights for FM101 to ‘HK Inno.N Co., Ltd.’

Additionally, Future Medicine holds various new drug candidates including the targeted anticancer drug ‘FM301,’ for which patent co-ownership technology transfer was completed to ‘Arontier,’ the broad-spectrum antiviral drug ‘FM203’ prepared for the next pandemic, pipelines under non-clinical research, and the immuno-oncology drug ‘FM401,’ which completed non-clinical trials and signed a joint clinical agreement with ‘GI Innovation.’

Recently, Future Medicine discovered the obesity treatment candidate ‘FM801’ and incorporated it as a new pipeline. Unlike existing GLP-1 class injectable obesity treatments, it is being developed with a mechanism that simultaneously regulates A2A and A3 adenosine receptors. By promoting energy metabolism through adipocyte conversion, it minimizes various side effects and offers patient convenience as an oral drug, securing multiple comparative advantages. Currently, non-clinical trials are underway as a project of the Korea Drug Development Fund (KDDF), with the goal of rapid clinical entry after non-clinical completion.

Jeong Nak-sin, CEO of Future Medicine, said, “Future Medicine is a new drug development company that discovers and continuously researches new drug candidates through the unique nucleoside platform ‘FOCUS.’ We will focus on new drug development based on the research and development capabilities accumulated over a long period and contribute to global health care.”

This content was produced with the assistance of AI translation services.